Comparative-effectiveness research, provided for in House and Senate healthcare overhaul legislation, can fill in the gaps left by standard clinical trials by pinpointing subpopulations that respond to a particular drug, Bill Crown, president of i3 Innovus, a health economics and outcomes research consulting company based in Ann Arbor, Mich., said. “The key to detecting subgroup differences is analysis of real-world data,” he said.
Washington Drug Letter